Executive interview – Verona Pharma

Published on 10 December 2018

Verona Pharma’s chairman, Dr David Ebsworth, provides an overview of the group’s core technology and applications, corporate strategy and development plans for its lead product, RPL554. He also outlines expected near-term news flow and the regulatory strategy.

Share this with friends and colleagues